Retrophin, Inc. Contracts & Agreements

Underwriting Agreement, dated November 7, 2024, by and among Travere Therapeutics, Inc., Jefferies LLC and Leerink Partners LLC (Filed With SEC on November 8, 2024)

Amended and Restated Open Market Sale Agreement, dated October 31, 2024, by and between the Company and Jefferies LLC (Filed With SEC on October 31, 2024)

Amendment No. 5 to Sublicense Agreement, dated as of March 20, 2018, between the Company and Ligand Pharmaceuticals Incorporated (Filed With SEC on October 31, 2024)

Non-Employee Director Compensation Program, as amended (Filed With SEC on May 6, 2024)

Non-Employee Director Compensation Program, as amended (Filed With SEC on February 20, 2024)

The Company's 202 (Filed With SEC on February 20, 2024)

Trademark License and Supply Agreement, dated May 29, 2014, by and between the Company and Mission Pharmacal Company (Filed With SEC on February 20, 2024)

Third Amendment to Trademark License and Supply Agreement dated as of March 17, 2016, between the Company and Mission Pharmacal Company (Filed With SEC on February 20, 2024)

Amendment One to the Third Amendment to Trademark License and Supply Agreement, dated September 12, 2016, by and between the Company and Mission Pharmacal Company (Filed With SEC on February 20, 2024)

Amendment Two to the Third Amendment to Trademark License and Supply Agreement, dated November 3, 2017, by and between the Company and Mission Pharmacal Company (Filed With SEC on February 20, 2024)

Fifth Amendment to Trademark License and Supply Agreement dated as of September 30, 2020, between the Company and Mission Pharmacal Company (Filed With SEC on February 20, 2024)

Asset Purchase Agreement, dated January 10, 2015, by and between the Company and Asklepion Pharmaceuticals, LLC (Filed With SEC on August 3, 2023)

Asset Purchase Agreement, dated July 16, 2023, by and between Mirum Pharmaceuticals, Inc., and Travere Therapeutics, Inc (Filed With SEC on July 17, 2023)

Employment Agreement, effective January 1, 2022, between the Company and Jula Inrig, M.D (Filed With SEC on May 4, 2023)

Underwriting Agreement, dated February 28, 2023, by and among Travere Therapeutics, Inc., Jefferies LLC, J.P. Morgan Securities LLC, BofA Securities, Inc. and SVB Securities LLC (Filed With SEC on March 1, 2023)

Form of Pre-Funded Warrant (Filed With SEC on March 1, 2023)

The Company's 2023 Executive Officer Annual Bonus Plan (Filed With SEC on February 23, 2023)

First Amendment to Master Manufacturing Supply Agreement, effective as of November 14, 2022, between the Company and STA Pharmaceutical Hong Kong Limited, a subsidiary of WuXi... (Filed With SEC on February 23, 2023)

Amendment No. 1 to the License and Collaboration Agreement, effective as of October 5, 2022, by and between Travere Therapeutics Switzerland GmbH (formerly known as Orphan... (Filed With SEC on February 23, 2023)

Employment Agreement, effective September 1, 2022, between the Company and Christopher Cline (Filed With SEC on August 17, 2022)

Non-Employee Director Compensation Program, as amended (Filed With SEC on May 5, 2022)

Retirement and Transition Agreement dated April 19, 2022, between the Company and Laura Clague (Filed With SEC on April 20, 2022)

Underwriting Agreement, dated March 8, 2022, by and among the Company, Jefferies LLC, SVB Securities LLC, BofA Securities, Inc. and Evercore Group L.L.C (Filed With SEC on March 11, 2022)

Second Supplemental Indenture, dated March 11, 2022, between the Company and U.S. Bank Trust Company, National Association, as Trustee (including the form of 2.25% Convertible... (Filed With SEC on March 11, 2022)

Description of Common Stock (Filed With SEC on February 24, 2022)

The Company's 2022 Executive Officer Annual Bonus Plan (Filed With SEC on February 24, 2022)

Form of Stock Option Grant Notice, Option Agreement and Exercise Notice for use under the Company's 2018 Equity Incentive Plan, as amended (Filed With SEC on February 24, 2022)

Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement for use under the Company's 2018 Equity Incentive Plan, as amended (Filed With SEC on February 24, 2022)

Sublicense Agreement, dated February 16, 2012, by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation, Pharmacopeia, Inc., a Delaware limited liability company,... (Filed With SEC on February 24, 2022)

Amendment No. 3 to Sublicense Agreement dated as of February 27, 2015, between the Company and Ligand Pharmaceuticals Incorporated (Filed With SEC on February 24, 2022)

Amendment No. 4 to Sublicense Agreement dated as of September 17, 2015, between the Company and Ligand Pharmaceuticals Incorporated (Filed With SEC on February 24, 2022)

Commercial Supply Agreement, dated December 21, 2021, between the Company and Catalent Pharma Solutions, LLC (Filed With SEC on February 24, 2022)

Consulting Services Agreement dated January 1, 2022, between the Company and Noah Rosenberg, M.D (Filed With SEC on January 6, 2022)

License and Collaboration Agreement, dated September 15, 2021, by and among Orphan Technologies Limited and Vifor (International) Ltd., and, solely with respect to Article 15, the... (Filed With SEC on October 29, 2021)

Transition Agreement dated October (Filed With SEC on October 12, 2021)

Description of Common Stock (Filed With SEC on March 1, 2021)

The Company's 2021 Executive Officer Annual Bonus Plan (Filed With SEC on March 1, 2021)

Underwriting Agreement, dated February 11, 2021, by and among Travere Therapeutics, Inc., BofA Securities, Inc., Jefferies LLC and SVB Leerink LLC, as representatives of the... (Filed With SEC on February 12, 2021)

Stock Purchase Agreement, dated October 21, 2020, by and among the Company, Orphan Technologies Limited and Citco Trustees (Cayman) Limited acting solely in its capacity as the... (Filed With SEC on November 18, 2020)

Master Manufacturing Supply Agreement, dated September 30, 2020, between the Company and STA Pharmaceutical Hong Kong Limited, a subsidiary of WuKi AppTec (Filed With SEC on November 5, 2020)

Fifth Amendment to Trademark License and Supply Agreement, effective September 30, 2020, between the Company and Mission Pharmacal Company (Filed With SEC on November 5, 2020)

Underwriting Agreement, dated June 8, 2020, by and among Retrophin, Inc., Jefferies LLC, Barclays Capital Inc. and BofA Securities, Inc., as representatives of the several... (Filed With SEC on June 9, 2020)

Non-Employee Director Compensation Program, as amended (Filed With SEC on May 11, 2020)

Employment Agreement, dated October 1, 2019, by and between the Company and Peter Heerma (Filed With SEC on May 11, 2020)

2020 Retrophin, Inc. Executive Officer Annual Bonus Plan (Filed With SEC on May 11, 2020)

Open Market Sales Agreement, dated February 24, 2020, by and between Retrophin, Inc. and Jefferies LLC (Filed With SEC on February 24, 2020)

Description of Common Stock (Filed With SEC on February 24, 2020)

Non-Employee Director Compensation Program (Filed With SEC on February 24, 2020)

Office Lease, effective April 12, 2019, between the Company and Kilroy Realty, L.P (Filed With SEC on August 6, 2019)

Separation Agreement between Retrophin Inc. and Neil McFarlane dated April 19, 2019 (Filed With SEC on April 19, 2019)

Fourth Amendment to Trademark License and Supply Agreement dated as of November 28, 2018, between Retrophin Inc. and Mission Pharmacal (Filed With SEC on February 26, 2019)

2019 Retrophin, Inc. Executive Officer Annual Bonus Plan (Filed With SEC on February 26, 2019)

Retirement Agreement, dated January 4, 2019, by and between the Company and Stephan Aselage (Filed With SEC on February 26, 2019)

Employment Agreement, dated January 4, 2019, by and between the Company and Eric M. Dube (Filed With SEC on February 26, 2019)

Employment Agreement, dated July 26, 2018, by and between the Company and Noah Rosenberg, M.D (Filed With SEC on February 26, 2019)

Underwriting Agreement, dated September 5, 2018, by and among the Company, Jefferies LLC, and Barclays Capital Inc (Filed With SEC on September 10, 2018)

Base Indenture, dated September 10, 2018, between the Company and U.S. Bank National Association, as Trustee (Filed With SEC on September 10, 2018)

First Supplemental Indenture, dated September 10, 2018, between the Company and U.S. Bank National Association, as Trustee (including the form of 2.50% Convertible Senior Note due... (Filed With SEC on September 10, 2018)

Form of Indemnity Agreement (Filed With SEC on May 1, 2018)

Amendment No. 5 to Sublicense Agreement dated as of March 20, 2018, between the Company and Ligand Pharmaceuticals Incorporated (Filed With SEC on May 1, 2018)

Employment Agreement, dated February 13, 2017, and Amendment to Employment Agreement, dated April 11, 2017, by and between the Company and William Rote (Filed With SEC on May 1, 2018)

Employment Agreement, dated February 6, 2017, and Amendment to Employment Agreement, dated April 11, 2017, by and between the Company and Elizabeth E. Reed (Filed With SEC on May 1, 2018)

Amendment Two to the Third Amendment to Trademark License and Supply Agreement, dated November 3, 2017, by and between the Company and Mission Pharmacal Company (Filed With SEC on February 27, 2018)

RETROPHIN, INC. Amendment to Employment Agreement (Filed With SEC on May 5, 2017)

2017 Retrophin, Inc. Executive Officer Annual Bonus Plan (Filed With SEC on March 1, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on November 4, 2016)

AMENDMENT ONE TO THE THIRD AMENDMENT TO TRADEMARK LICENSE AND SUPPLY AGREEMENT (Filed With SEC on November 4, 2016)

ASSET PURCHASE AGREEMENT (Filed With SEC on August 5, 2016)

SECOND AMENDMENT TO TRADEMARK LICENSE AND SUPPLY AGREEMENT (Filed With SEC on May 5, 2016)

THIRD AMENDMENT TO TRADEMARK LICENSE AND SUPPLY AGREEMENT (Filed With SEC on May 5, 2016)

AMENDMENT NO. 4 TO SUBLICENSE AGREEMENT (Filed With SEC on November 6, 2015)

ASSET PURCHASE AGREEMENT BY AND BETWEEN SANOFI AND RETROPHIN, INC. May 22, 2015 ASSET PURCHASE AGREEMENT (Filed With SEC on May 27, 2015)

ASSET PURCHASE AGREEMENT (Filed With SEC on May 11, 2015)

Amendment No. 3 to Credit Agreement (Filed With SEC on May 11, 2015)

AMENDMENT NO. 3 TO SUBLICENSE AGREEMENT (Filed With SEC on May 11, 2015)

ASSET PURCHASE AGREEMENT (Filed With SEC on May 11, 2015)

Amendment No. 4 to Credit Agreement (Filed With SEC on May 11, 2015)

EMPLOYMENT AGREEMENT (Filed With SEC on May 11, 2015)

PURCHASE AGREEMENT (Filed With SEC on May 11, 2015)

6,840,000 Shares RETROPHIN, INC. CommonStock, Par Value $0.0001 Per Share UNDERWRITING AGREEMENT (Filed With SEC on March 19, 2015)

EMPLOYMENT AGREEMENT (Filed With SEC on March 11, 2015)

Summary SeparationProposal (Filed With SEC on March 11, 2015)

$45,000,000 CREDIT AGREEMENT dated as of June 30, 2014 among RETROPHIN, INC., as Borrower, the LENDERS from time to time parties hereto and U.S. BANK NATIONAL ASSOCIATION, as... (Filed With SEC on November 13, 2014)

Amendment No. 1 to Credit Agreement (Filed With SEC on November 13, 2014)

Amendment No. 2 to Credit Agreement (Filed With SEC on November 13, 2014)

FIRST AMENDMENT TO TRADEMARK LICENSE AND SUPPLY AGREEMENT (Filed With SEC on July 29, 2014)

COMMON STOCK PURCHASE WARRANT CERTIFICATE RETROPHIN, INC. Warrants: _______Initial Exercise Date: June 30, 2014 (Filed With SEC on July 7, 2014)

$45,000,000 CREDIT AGREEMENT dated as of June 30, 2014 among RETROPHIN, INC., as Borrower, the LENDERS from time to time parties hereto and U.S. BANK NATIONAL ASSOCIATION, as... (Filed With SEC on July 7, 2014)

GUARANTEE AND COLLATERAL AGREEMENT dated as of June 30, 2014, among RETROPHIN, INC., as the Borrower THE GUARANTORS PARTY HERETO and U.S. BANK NATIONAL ASSOCIATION, as Collateral... (Filed With SEC on July 7, 2014)

Signature Page to Retrophin Note Purchase Agreement (Filed With SEC on June 4, 2014)

Retrophin, Inc. 4.50% Senior Convertible Notes due 2019 (Filed With SEC on June 4, 2014)

Trademark License & Supply Agreement (Filed With SEC on June 4, 2014)

EMPLOYMENT AGREEMENT (Filed With SEC on June 4, 2014)

EMPLOYMENT AGREEMENT (Filed With SEC on June 3, 2014)

INTERNATIONAL RIGHTS PURCHASE AGREEMENT (Filed With SEC on March 31, 2014)

MEMBERSHIP INTEREST PURCHASE AGREEMENT by and among Retrophin, Inc., on the one hand, and Loring Creek Holdings LLC, Lloyd Glenn and Matthias Kurth (collectively, the Sellers) on... (Filed With SEC on March 31, 2014)

SECURED PROMISSORY NOTE (Filed With SEC on March 31, 2014)

MEMBERSHIP INTEREST PLEDGE AGREEMENT (Filed With SEC on March 31, 2014)

SECURITY AGREEMENT (Filed With SEC on March 31, 2014)

Stock Purchase Agreement (Filed With SEC on January 7, 2014)

SECOND AMENDMENT TO SECURITIES PURCHASE AGREEMENT (Filed With SEC on January 7, 2014)

FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT (Filed With SEC on January 7, 2014)

4,820,000 Shares Retrophin, Inc. UNDERWRITING AGREEMENT (Filed With SEC on January 7, 2014)

EXECUTION VERSION Stock Purchase Agreement by and among Retrophin, Inc. as Buyer, Kyalin Biosciences, Inc., As the Company, and the Sellers party hereto Dated: December 23, 2013... (Filed With SEC on December 30, 2013)

LICENSE AGREEMENT between NOVARTIS PHARMA AG NOVARTIS AG and RETROPHIN, INC. Table of Contents (Filed With SEC on December 18, 2013)

EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on December 18, 2013)

SPONSORED RESEARCH AGREEMENT (Filed With SEC on December 18, 2013)

EMPLOYMENT AGREEMENT (Filed With SEC on December 18, 2013)

SPONSORED RESEARCH AGREEMENT (Filed With SEC on December 5, 2013)

SPONSORED RESEARCH AGREEMENT (Filed With SEC on November 15, 2013)

SETTLEMENT AND RELEASE AGREEMENT (Filed With SEC on November 15, 2013)

[MSMB LETTERHEAD] (Filed With SEC on November 15, 2013)

PROMISSORY NOTE $[______]New York, New York[_________], 2013 (Filed With SEC on November 15, 2013)

COMMON STOCK PURCHASE WARRANT RETROPHIN, INC. Warrant Shares: _______Initial Exercise Date: August 15, 2013 (Filed With SEC on August 20, 2013)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on August 20, 2013)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on August 20, 2013)

FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT (Filed With SEC on August 20, 2013)

FIRST AMENDMENT TO REGISTRATION RIGHTS AGREEMENT (Filed With SEC on August 20, 2013)

AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on July 30, 2013)

EMPLOYMENT AGREEMENT (Filed With SEC on April 26, 2013)

COMMON STOCK PURCHASE WARRANT DESERT GATEWAY, INC. Warrant No.Warrant Shares: _______Initial Exercise Date: February 14, 2013 (Filed With SEC on February 19, 2013)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on February 19, 2013)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on February 19, 2013)

PLAN AND AGREEMENT OF MERGER (Filed With SEC on December 19, 2012)

SUBLICENSE AGREEMENT (Filed With SEC on December 19, 2012)

Category

Industry

Companies

Contracts

Retrophin, Inc. Contracts & Agreements